Alendronate Tablets   3

Background
The Department of Veterans Affairs (VA) is issuing this solicitation to establish a supply source for Alendronate Tablets through the VA Pharmaceutical Prime Vendor (PPV) Program. The goal of this contract is to ensure the availability and consistency of pharmaceutical products for nationwide usage while obtaining volume-based pricing. The contract will support various government health facilities including VA, Federal Health Care Centers, State Veterans Homes, Indian Health Service, and Bureau of Prisons.

Work Details
The contract includes the supply of Alendronate Tablets in various packaging options as follows:

1. **Alendronate 35MG Tablets**
- **Packaging**: 4 Count Bottle (BT) or 4 Count Blister Pack (BP)
- **Quantity**: 21,300 units per year for Base Year and each Option Year (1-4)

2. **Alendronate 35MG Tablets**
- **Packaging**: 12 Count Bottle (BT) or 12 Count Blister Pack (BP)
- **Quantity**: 5,354 units per year for Base Year and each Option Year (1-4)

3. **Alendronate 70MG Tablets**
- **Packaging**: 4 Count Bottle (BT) or 4 Count Blister Pack (BP)
- **Quantity**: 80,074 units per year for Base Year and each Option Year (1-4)

4. **Alendronate 70MG Tablets**
- **Packaging**: 12 Count Bottle (BT) or 12 Count Blister Pack (BP)
- **Quantity**: 100,609 units per year for Base Year and each Option Year (1-4)

All packaging must meet specific requirements including safety caps and bottle dimensions as outlined in the solicitation. Offerors must provide an NDC number unique to their company for each drug offered.

Period of Performance
The contract will be effective upon signing by the VA and will include a base year with four option years.

Place of Performance
Products will be delivered to various locations as specified by the VA PPV Program, including all Department of Veterans Affairs facilities, Indian Health Service facilities, Bureau of Prisons facilities, and State Veterans Homes.